The Technical Analyst
Vera Therapeutics, Inc. [VERA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Vera Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-1.32% $39.48
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 168.12 mill |
| EPS: | -2.25 |
| P/E: | -17.55 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 54.92 mill |
| Avg Daily Volume: | 1.418 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -17.55 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.99x |
| Company: PE -17.55 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.188 (-100.48%) $-39.67 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 36.42 - 42.66 ( +/- 7.90%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-10 | Young Joseph R | Sell | 5 714 | Class A Common Stock |
| 2024-04-03 | Grant Sean | Buy | 99 828 | Class A Common Stock |
| 2024-04-03 | Grant Sean | Sell | 69 831 | Class A Common Stock |
| 2024-04-03 | Grant Sean | Sell | 10 988 | Class A Common Stock |
| 2024-04-03 | Grant Sean | Sell | 99 828 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 33.15 |
| Last 98 transactions |
| Buy: 7 469 518 | Sell: 2 159 720 |
Forecast:
16:00 - $39.55
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $39.55
Forecast 2: 16:00 - $39.55
Forecast 3: 16:00 - $39.55
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $39.48 (-1.32% ) |
| Volume | 0.842 mill |
| Avg. Vol. | 1.418 mill |
| % of Avg. Vol | 59.37 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VERA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $37.90 | N/A | Active |
|---|
VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Last 10 Buy Signals
Latest Press Releases
2024-03-20 07:30:00 - Press Release
Vera Therapeutics Provides Business Update And Reports Fourth Quarter And Full Year 2023 Financial Results
Brisbane, calif., march 20, 2024 (globe newswire) -- vera therapeutics, inc. (nasdaq: vera), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today reported its business highlights and financial results for the fourth quarter and year ended december 31, 2023.
2024-02-28 16:20:00 - Press Release
Vera Therapeutics To Participate At The 44th Annual Td Cowen Health Care Conference
Brisbane, calif., feb. 28, 2024 (globe newswire) -- vera therapeutics, inc. (nasdaq: vera), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the company's management team will participate in the 44th annual td cowen health care conference, which is taking place from march 4th to 6th at the marriott copley place in boston, ma.
2024-02-02 08:00:00 - Press Release
Vera Therapeutics To Participate In The Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Brisbane, calif., feb. 02, 2024 (globe newswire) -- vera therapeutics, inc. (nasdaq: vera), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the company's management team will participate in the 6th annual guggenheim biotechnology conference, which is taking place in new york on february 7th and 8th.
2024-02-01 16:05:00 - Press Release
Vera Therapeutics Announces Closing Of Upsized Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares In Public Offering Of Class A Common Stock
Brisbane, calif., feb. 01, 2024 (globe newswire) -- vera therapeutics, inc. (“vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the closing of its previously announced underwritten public offering of 9,274,194 shares of its class a common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,209,677 shares, at a price to the public of $31.00 per share. the gross proceeds to vera from the offering, before deducting underwriting discounts and commissions and offering expenses, are approximately $287.5 million.
2024-01-29 23:50:00 - Press Release
Vera Therapeutics Announces Pricing Of Upsized Public Offering Of Class A Common Stock
Brisbane, calif., jan. 29, 2024 (globe newswire) -- vera therapeutics, inc. (“vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an upsized underwritten public offering of 8,064,517 shares of its class a common stock at a price to the public of $31.00 per share.
Latest News
2024-04-13 05:29:00 - The Motley Fool
Could This Stock Be the Next Biotech Buyout?
Vera Therapeutics is developing a dual-action antibody to treat kidney disorders, with successful results from the first portion of a pivotal study. Recently, Vertex Pharmaceuticals acquired Alpine Immune Sciences, another company developing an antibody that binds to the same receptors as Vera Therapeutics' candidate.
2024-04-11 13:41:46 - Schaeffers Research
2 Biotech Stocks Driving the Nasdaq Today
The Nasdaq is leading the charge today, with biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) up over 2% today.
2024-01-12 18:44:15 - The Motley Fool
Why Vera Therapeutics Stock Soared by 22% This Week
The biotech added two new executives to its ranks. Both have considerable experience in healthcare industry management.
2023-12-15 10:15:00 - The Motley Fool
This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street
Vera Therapeutics is a clinical stage company that some analysts think could be worth $1 billion. The company could have an approved product for the treatment of IgA nephropathy by 2026.
2023-10-30 08:00:00 - GlobeNewsWire
Vera Therapeutics Scheduled to Present at November Investor Conferences
BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at the following investor conferences, as detailed below:
2023-10-18 11:19:56 - Zacks Investment Research
Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)
The heavy selling pressure might have exhausted for Vera Therapeutics, Inc. (VERA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2023-10-17 11:19:30 - Zacks Investment Research
Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. (VERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2023-10-16 11:18:39 - Zacks Investment Research
Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a Turnaround
Vera Therapeutics, Inc. (VERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2023-10-13 10:22:00 - GlobeNewsWire
Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting
Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting atacicept's potential as long-term disease-modifying IgAN therapy Atacicept showed continued protective titers to diphtheria and tetanus and balanced COVID infections vs. placebo in IgAN BRISBANE, Calif.
2023-08-15 17:42:07 - Zacks Investment Research
What Makes Vera Therapeutics, Inc. (VERA) a New Buy Stock
Vera Therapeutics, Inc. (VERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.